Nvest Financial LLC Has $833,000 Stake in Stryker Co. (NYSE:SYK)

Nvest Financial LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 46.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,313 shares of the medical technology company’s stock after acquiring an additional 736 shares during the quarter. Nvest Financial LLC’s holdings in Stryker were worth $833,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR grew its stake in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Stryker in the 3rd quarter valued at about $36,000. HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter worth approximately $42,000. Finally, Hara Capital LLC acquired a new stake in Stryker during the third quarter worth approximately $42,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SYK. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird lifted their target price on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Truist Financial upped their price target on shares of Stryker from $380.00 to $409.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Barclays lifted their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company raised their target price on shares of Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $411.30.

Insider Activity at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by company insiders.

Stryker Trading Down 1.2 %

NYSE SYK opened at $394.92 on Wednesday. Stryker Co. has a twelve month low of $310.74 and a twelve month high of $406.19. The business’s fifty day moving average is $376.44 and its 200 day moving average is $361.98. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company has a market cap of $150.55 billion, a price-to-earnings ratio of 42.33, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter in the previous year, the company earned $3.46 EPS. As a group, sell-side analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. Stryker’s payout ratio is currently 36.01%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.